Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 77 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: azathioprine Clear all
Recruiting No phase listed Observational

Registry for Systemic Eczema Treatments

NCT06136767
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
1 Year to 26 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 21, 2026, 6:01 PM EDT
Not listed Phase 4 Interventional

Acthar Gel for Chronic Pulmonary Sarcoidosis (ACPS)

NCT02188017
View directory record Official record
Conditions
Sarcoidosis, Pulmonary Sarcoidosis
Interventions
Acthar gel
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 8, 2015 · Synced Oct 21, 2026, 6:01 PM EDT
Completed Phase 4 Interventional Results available

Predicting Response to Standardized Pediatric Colitis Therapy

NCT01536535
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Mesalazine, IV Corticosteroid, Oral Corticosteroids, Additional Therapies, Colectomy
Drug · Other · Procedure
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
4 Years to 17 Years
Enrollment
431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
26
States / cities
Los Angeles, California • San Francisco, California • Hartford, Connecticut + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2019 · Synced Oct 21, 2026, 6:01 PM EDT
Terminated Phase 2 Interventional

Imuran Dosing in Crohn's Disease Study

NCT00113503
View directory record Official record
Conditions
Crohn's Disease
Interventions
Azathioprine weight-based dose, Azathioprine individualised dose
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
10 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
12
States / cities
Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 21, 2026, 6:01 PM EDT
Recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Uterus Transplantation to Treat Infertility

NCT05646992
View directory record Official record
Conditions
Uterine Factor Infertility
Interventions
Uterine Allotransplantation, Tacrolimus, Imuran
Procedure · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 38 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2043
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 21, 2026, 6:01 PM EDT
Terminated Phase 2 Interventional Results available

LCP-Tacro vs. Azathioprine for the Treatment of Autoimmune Hepatitis

NCT00608894
View directory record Official record
Conditions
Autoimmune Hepatitis
Interventions
LCP-Tacro (tacrolimus), Azathioprine
Drug
Lead sponsor
Veloxis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
8
States / cities
Phoenix, Arizona • Jacksonville, Florida • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Oct 21, 2026, 6:01 PM EDT
Not listed Early Phase 1 Interventional

Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in SLE

NCT04726553
View directory record Official record
Conditions
Systemic Lupus Erythematosus (SLE)
Interventions
Anifrolumab, Standard of Care
Drug
Lead sponsor
Oklahoma Medical Research Foundation
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
New Haven, Connecticut • Atlanta, Georgia • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Oct 21, 2026, 6:01 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus

NCT02349061
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Ustekinumab IV, Placebo Infusion, Placebo SC, Ustekinumab SC, Concomitant Medication
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
12
States / cities
Huntsville, Alabama • Beverly Hills, California • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Oct 21, 2026, 6:01 PM EDT
Completed Phase 3 Interventional Results available

Rituximab Vasculitis Maintenance Study

NCT01697267
View directory record Official record
Conditions
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Microscopic Polyangiitis, Wegener Granulomatosis
Interventions
Rituximab, Azathioprine
Biological · Drug
Lead sponsor
Cambridge University Hospitals NHS Foundation Trust
Other
Eligibility
15 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
9
States / cities
Los Angeles, California • Ann Arbor, Michigan • Rochester, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2022 · Synced Oct 21, 2026, 6:01 PM EDT
Completed Phase 3 Interventional Results available

A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.

NCT00377637
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Mycophenolate mofetil (MMF), Cyclophosphamide, Azathioprine, Placebo to Azathioprine, Placebo to Mycophenolate mofetil, Corticosteroid
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years to 75 Years
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
28
States / cities
Huntsville, Alabama • La Jolla, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2011 · Synced Oct 21, 2026, 6:01 PM EDT
Recruiting Phase 2 Interventional

Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease

NCT07616154
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Cyclophosphamide 50mg, Abatacept, Alemtuzumab, Hydroxyurea, Thiotepa, Filgrastim, Sirolimus, Azathioprine, TBI, Hematopoietic Progenitor Cell Infusion
Drug · Radiation · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 22 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 21, 2026, 6:01 PM EDT
Active, not recruiting Phase 2 Interventional

Haplo T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease

NCT01461837
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
CD34 selected T-cell depleted allogeneic SCT
Drug
Lead sponsor
New York Medical College
Other
Eligibility
2 Years to 20 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
6
States / cities
Los Angeles, California • Oakland, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2025 · Synced Oct 21, 2026, 6:01 PM EDT
Completed Phase 3 Interventional Results available

An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies

NCT00720798
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tocilizumab, Disease-modifying anti-rheumatic drugs, Non-steroidal anti-inflammatory drugs, Oral corticosteroids
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
2,067 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
138
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 119 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2014 · Synced Oct 21, 2026, 6:01 PM EDT
Recruiting Phase 2 Interventional

Pragmatic, Open-Label Study to Pilot Evaluation for Clinical Trials in Relapsing Polychondritis

NCT06941376
View directory record Official record
Conditions
Relapsing Polychondritis
Interventions
Methotrexate (MTX), Azathioprine (AZA), Adalimumab, Infliximab, Tocilizumab
Drug · Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 21, 2026, 6:01 PM EDT
Completed Phase 2 Interventional Results available

Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis

NCT00774852
View directory record Official record
Conditions
Lupus Nephritis, Lupus Erythematosus, Systemic
Interventions
abatacept, cyclophosphamide, azathioprine, prednisone, abatacept placebo, azathioprine placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
21
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Oct 21, 2026, 6:01 PM EDT
Active, not recruiting Phase 2 Interventional

Reduced Intensity Transplantation for Severe Sickle Cell Disease

NCT04362293
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
hydroxyurea, azathioprine, alemtuzumab, thioptepa, low dose total body irradiation and sirolimus, hydroxyurea, azathioprine, alemtuzumab, thiotepa, plerixafor, low dose total body irradiation, cyclophosphamide and sirolimus
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
2 Years to 25 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 21, 2026, 6:01 PM EDT
Completed Phase 3 Interventional Results available

Trial Comparing Infliximab and Infliximab and Azathioprine in the Treatment of Patients With Crohn's Disease na�ve to Both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naive Patients in Chrohn's Disease: SONIC

NCT00094458
View directory record Official record
Conditions
Crohn Disease
Interventions
infliximab infusion; AZA placebo caps, infliximab (IFX) infusion; azathioprine (AZA) caps, infliximab (IFX) placebo infusion; azathioprine (AZA) caps
Biological · Other · Drug
Lead sponsor
Centocor Ortho Biotech Services, L.L.C.
Industry
Eligibility
21 Years to 99 Years
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
51
States / cities
Birmingham, Alabama • Phoenix, Arizona • Orange, California + 48 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Oct 21, 2026, 6:01 PM EDT
Not listed Phase 3 Interventional

Cimzia Versus Cimzia Plus Azathioprine in the Treatment of Active Crohn's Disease

NCT01817972
View directory record Official record
Conditions
Crohn's Disease
Interventions
Certolizumab pegol, Azathioprine
Biological · Drug
Lead sponsor
Gastroenterology Research of America
Other
Eligibility
18 Years to 70 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 26, 2013 · Synced Oct 21, 2026, 6:01 PM EDT
Enrolling by invitation Not applicable Interventional

Expanding and Promoting Alternative Care and kNowledge in Decision-making Trial

NCT06243068
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Educate and Engage, Educate and Engage Plus Kidney Supportive Care Program
Behavioral
Lead sponsor
George Washington University
Other
Eligibility
65 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
25
States / cities
San Francisco, California • Washington D.C., District of Columbia • Canton, Georgia + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 21, 2026, 6:01 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cross Sectional Study of Vaccine Antibody Response in Inflammatory Bowel Disease Patients

NCT02434133
View directory record Official record
Conditions
Inflammatory Bowel Disease (IBD)
Interventions
Blood Draw/Data Collection
Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 65 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 27, 2018 · Synced Oct 21, 2026, 6:01 PM EDT
Completed No phase listed Observational

Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab

NCT03056924
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
Pneumococcal Pneumonia vaccine, Influenza vaccine, Hepatitis B vaccine
Biological
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 30, 2019 · Synced Oct 21, 2026, 6:01 PM EDT
Terminated Phase 4 Interventional Results available

Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib

NCT03591770
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
SHINGRIX
Biological
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 21, 2025 · Synced Oct 21, 2026, 6:01 PM EDT
Terminated Phase 3 Interventional Results available

A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura)

NCT01433978
View directory record Official record
Conditions
Idiopathic Thrombocytopenic Purpura
Interventions
Eltrombopag, Avatrombopag, Standard of care
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Watertown, South Dakota
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Oct 21, 2026, 6:01 PM EDT
Completed Phase 3 Interventional Results available

Adalimumab vs. Conventional Immunosuppression for Uveitis Trial

NCT03828019
View directory record Official record
Conditions
Uveitis
Interventions
Adalimumab (ADA), Conventional immunosuppression (CON)
Biological · Drug
Lead sponsor
JHSPH Center for Clinical Trials
Other
Eligibility
13 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
19
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 21, 2026, 6:01 PM EDT